Taking a Symptom-Based Approach to Parkinson Disease Psychosis: Aaron Ritter, MDMay 23rd 2023
The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute discussed the future of treating Parkinson disease psychosis, and potential ways to lower risk of poor long-term outcomes. [WATCH TIME: 3 minutes]
Contaminated Drinking Water, Environmental Factors May Increase Risk of Parkinson DiseaseMay 23rd 2023
A recent published study highlighted the importance of environmental risk factors for Parkinson disease, such as exposure to trichloroethylene and other volatile organic compounds.
Pridopidine’s Impact on ALS, Assessing Results From HEALEY ALS Platform Trial: Melanie Leitner, PhDMay 23rd 2023
The consultant and founder of Accelerating NeuroVentures talked about the pridopidine arm from the HEALEY ALS Platform trial, which showed significant benefits in speech measures. [WATCH TIME: 5 minutes]
Research Identifies Links Between Proinflammatory Diets and Increased Relapses, Lesion Volume in Multiple SclerosisMay 23rd 2023
Clinically relevant effect sizes were observed, with those in the highest Dietary Inflammatory Index quartile having relapse risk 2.45 times higher than those in the lowest quartile.
Researchers Identify Association Between Physical Activity and Spinal Cord Gray Matter Area in Multiple SclerosisMay 22nd 2023
Findings showed that greater average daily step count was significantly correlated with greater C2-C3 spinal cord gray matter areas, total cord area, and cortical gray matter volume.
Potential for Combination Approaches in Multiple Sclerosis and Role of CNM-Au8: Michael Barnett, PhD, MBBS, FRACPMay 22nd 2023
The senior academic at the University of Sydney provided perspective on the role of CNM-Au8 in MS among a crowded treatment landscape, and the need for adjuvant treatments that address lingering lesion burden. [WATCH TIME: 3 minutes]
Lacosamide Provides Benefit as Second-Line Treatment for Refractory Trigeminal NeuralgiaMay 21st 2023
To date, in the largest series of patients treated with lacosamide after first-line treatment failure, pain relief was achieved in 66% of patients, with a relatively low proportion of mild adverse events.
Combining Brain-Computer Interface with Augmented Reality for Neurodegenerative Diseases: Andreas ForslandMay 21st 2023
The chief executive officer of Cognixion talked about the Cognixion ONE Axon, a wireless, wearable brain-computer interface that combines EEG technology with an augmented reality headset for patients with neurodegenerative diseases. [WATCH TIME: 4 minutes]
Long-term Function Decline and Rehabilitation Therapy Utilization PoststrokeMay 20th 2023
Steven C. Cramer, MD, stroke neurologist and professor of neurology at UCLA, talked about the 3 main types of rehab therapy given to poststroke patients and the significant disparities in access.
Potential Path for Phase 3 Study of AOC 1001 in Myotonic Dystrophy Becomes Clear After FDA Ease’s Clinical HoldMay 20th 2023
The phase 1/2 MARINA trial assessed the activity of AOC 1001 across key biomarkers, including spliceopathy, an important biomarker for myotonic dystrophy type 1, and knockdown of DMPK mRNA.
Expanding Diversity in Neurology, Inclusive Communication and Accessibility: Diana M. Cejas, MD, MPHMay 19th 2023
The assistant professor of neurology at the University of North Carolina at Chapel Hill discussed the importance of recognizing disability as part of diversity in neurology, emphasizing the need for inclusive communication and accessibility for disabled patients. [WATCH TIME: 10 minutes]
The Classification, Management, and Future Directions of Neonatal Seizures: Elissa Yozawitz, MDMay 19th 2023
The associate professor of neurology at Albert Einstein College of Medicine talked about a review on neonatal seizures recently published in the New England Journal of Medicine. [WATCH TIME: 5 minutes]
Unveiling the Efficacy and Safety of LX9211 as a Treatment for Postherpetic NeuralgiaMay 18th 2023
Anand Patel, MD, CPI, chief medical officer at Conquest Research, discussed a phase 2 study that investigated the efficacy and safety of LX9211, an oral medication targeting neuropathic pain.
Potential for Preventing NMOSD, Improving Access to Panel Testing: Sean Pittock, MDMay 18th 2023
The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided commentary on the possibility of preventing NMOSD, and the need to improve access to approved therapies and AQP4 testing. [WATCH TIME: 3 minutes]
COVID-19 Severity in Pediatric Patients With MS on B-Cell-Depleting Therapies: Teri Schreiner, MDMay 18th 2023
The associate professor at the University of Colorado talked about a study involving pediatric patients with multiple sclerosis and related disorders, and the risk of COVID-19 infection among those on B-cell-depleting therapy. [WATCH TIME: 5 minutes]
Alzheimer Agent COYA 301 Halts Cognitive Decline, Restores Regulatory T Cell Dysfunction in Phase 1 StudyMay 17th 2023
Over a 4-month treatment period, the agent was well tolerated, with patients showing no significant changes in ADAS-Cog or CDR-SB scores, indicating no cognitive decline.
FDA Approves Abbott’s Spinal Cord Stimulation Systems for Chronic Back PainMay 17th 2023
Comprised of the recharge-free Proclaim SCS family and the rechargeable Eterna SCS platform, the approval for Abbott’s spinal cord stimulation system was backed by the large-scale, DISTINCT study.
Exploring the Risk of Hypertension Following Erenumab Treatment for Migraine: Nikita Chhabra, DOMay 17th 2023
The neurology PGY-3 at Mayo Clinic in Arizona talked about findings from a retrospective cohort study that examined blood pressure in patients who were prescribed a migraine medication. [WATCH TIME: 6 minutes]